Alexander Eustace
Dr.
Dr Eustace is a graduate of NUI Maynooth where he studied Biology and Chemistry. He then undertook a MSc in Biological Sciences in Dublin City University. Upon graduation Dr Eustace worked for a campus biotechnology company Archport Ltd, as a Downstream Process Technician/Manager.
in 2006 Dr Eustace returned to DCU to undertake his PhD in the field of Translational Oncology, graduating in 2010. He then undertook several post-doctoral positions both in DCU and the Royal College of Surgeons in Ireland, working as part of the MTCI (SFI) and BreastPredict (Irish Cancer Society) funded research centres.
In 2017 Dr Eustace returned to DCU as the research lead of Molecular Therapeutics for Cancer in ireland and more recently as Assistant Professor in the School of Biotechnology.
Peer Reviewed Journal
| Year | Publication | |
|---|---|---|
| 2025 | Zhou, Y.; Camisasca, A.; Dominguez-Gil, S.; Bartkowski, M.; Rochfort, K.D.; Piletti, M.; White, A.; Krizsan, D.; O'Connor, R.; Quinn, S.J.; Iacopino, D.; Eustace, A.J.; Giordani, S. (2025) 'Synthesis of carbon dots from spent coffee grounds: transforming waste into potential biomedical tools'. Nanoscale, . [Link] [DOI] | |
| 2024 | Lynch, S.M.; Heeran, A.B.; Burke, C.; Lynam-Lennon, N.; Eustace, A.J.; Dean, K.; Robson, T.; Rahman, A.; Marcone, S. (2024) 'Precision Oncology, Artificial Intelligence, and Novel Therapeutic Advancements in the Diagnosis, Prevention, and Treatment of Cancer: Highlights from the 59th Irish Association for Cancer Research (IACR) Annual Conference'. Cancers, 16 . [Link] [DOI] | |
| 2024 | Miceli, R.; Eriksson, H.; Russo, G.L.; Alfieri, S.; Bjaanæs, M.M.; Pietrantonio, F.; Cecco, L.D.; Prelaj, A.; Proto, C.; Franzén, J.; McDonnell, D.; Pina, J.J.B.; Beninato, T.; Mazzeo, L.; Giannatempo, P.; Verzoni, E.; Crown, J.; Helland, Å.; Eustace, A.J. (2024) 'Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study'. Acta Oncologica, 63 . [Link] [DOI] | |
| 2023 | Cosgrove, N.; Eustace, A.J.; O’Donovan, P.; Madden, S.F.; Moran, B.; Crown, J.; Moulton, B.; Morris, P.G.; Grogan, L.; Breathnach, O.; Power, C.; Allen, M.; Walshe, J.M.; Hill, A.D.; Blümel, A.; O’Connor, D.; Das, S.; Milewska, M.; Fay, J.; Kay, E.; Toomey, S.; Hennessy, B.T.; Furney, S.J. (2023) 'Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer'. NPJ breast cancer, 9 . [Link] [DOI] | |
| 2022 | Mukherjee, N.; Browne, A.; Ivers, L.; Santra, T.; Cremona, M.; Hennessy, B.T.; O’Donovan, N.; Crown, J.; Kolch, W.; Fey, D.; Eustace, A.J. (2022) 'A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin'. Journal of personalized medicine, 12 . [Link] [DOI] | |
| 2021 | Eustace, A.J.; Madden, S.F.; Fay, J.; Collins, D.M.; Kay, E.W.; Sheehan, K.M.; Furney, S.; Moran, B.; Fagan, A.; Morris, P.G.; Teiserskiene, A.; Hill, A.D.; Grogan, L.; Walshe, J.M.; Breathnach, O.; Power, C.; Duke, D.; Egan, K.; Gallagher, W.M.; O’Donovan, N.; Crown, J.; Toomey, S.; Hennessy, B.T. (2021) 'The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer'. Breast Cancer Research and Treatment, 187 . [Link] [DOI] | |
| 2021 | Collins, D.M.; Madden, S.F.; Gaynor, N.; AlSultan, D.; Le Gal, M.; Eustace, A.J.; Gately, K.A.; Hughes, C.; Davies, A.M.; Mahgoub, T.; Ballot, J.; Toomey, S.; O'Connor, D.P.; Gallagher, W.M.; Holmes, F.A.; Espina, V.; Liotta, L.; Hennessy, B.T.; O'Byrne, K.J.; Hasmann, M.; Bossenmaier, B.; O'Donovan, N.; Crown, J. (2021) 'Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer'. Clinical Cancer Research, 27 . [Link] [DOI] | |
| 2021 | AlSultan, D.; Kavanagh, E.; O’Grady, S.; Eustace, A.J.; Castell, A.; Larsson, L.G.; Crown, J.; Madden, S.F.; Duffy, M.J. (2021) 'The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells'. Investigational New Drugs, 39 . [Link] [DOI] | |
| 2020 | Kennedy, S.P.; O’Neill, M.; Cunningham, D.; Morris, P.G.; Toomey, S.; Blanco-Aparicio, C.; Martinez, S.; Pastor, J.; Eustace, A.J.; Hennessy, B.T. (2020) 'Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer'. Oncogene, 39 . [Link] [DOI] | |
| 2020 | Canonici, A.; Browne, A.L.; Ibrahim, M.F.K.; Fanning, K.P.; Roche, S.; Conlon, N.T.; O’Neill, F.; Meiller, J.; Cremona, M.; Morgan, C.; Hennessy, B.T.; Eustace, A.J.; Solca, F.; O’Donovan, N.; Crown, J. (2020) 'Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer'. Therapeutic Advances in Medical Oncology, 12 . [Link] [DOI] | |
| 2020 | Toomey, S.; Carr, A.; Mezynski, M.J.; Elamin, Y.; Rafee, S.; Cremona, M.; Morgan, C.; Madden, S.; Abdul-Jalil, K.I.; Gately, K.; Farrelly, A.; Kay, E.W.; Kennedy, S.; O'Byrne, K.; Grogan, L.; Breathnach, O.; Morris, P.G.; Eustace, A.J.; Fay, J.; Cummins, R.; O'Grady, A.; Kalachand, R.; O'Donovan, N.; Kelleher, F.; O'Reilly, A.; Doherty, M.; Crown, J.; Hennessy, B.T. (2020) 'Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples'. Journal of Translational Medicine, 18 . [Link] [DOI] | |
| 2020 | Breen, L.; Gaule, P.B.; Canonici, A.; Walsh, N.; Collins, D.M.; Cremona, M.; Hennessy, B.T.; Duffy, M.J.; Crown, J.; Donovan, N.O.; Eustace, A.J. (2020) 'Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A'. Investigational New Drugs, 38 . [Link] [DOI] | |
| 2019 | Brown, P.; Zhou, Y.; Tan, A.C.; El-Esawi, M.A.; Liehr, T.; Blanck, O.; Gladue, D.P.; Almeida, G.M.F.; Cernava, T.; Sorzano, C.O.; Yeung, A.W.K.; Engel, M.S.; Chandrasekaran, A.R.; Muth, T.; Staege, M.S.; Daulatabad, S.V.; Widera, D.; Zhang, J.; Meule, A.; Honjo, K.; Pourret, O.; Yin, C.C.; Zhang, Z.; Cascella, M.; Flegel, W.A.; Goodyear, C.S.; van Raaij, M.J.; Bukowy-Bieryllo, Z.; Campana, L.G.; Kurniawan, N.A.; Lalaouna, D.; Hüttner, F.J.; Ammerman, B.A.; Ehret, F.; Cobine, P.A.; Tan, E.C.; Han, H.; Xia, W.; McCrum, C.; Dings, R.P.M.; Marinello, F.; Nilsson, H.; Nixon, B.; Voskarides, K.; Yang, L.; Costa, V.D.; Bengtsson-Palme, J.; Bradshaw, W.; Grimm, D.G.; Kumar, N.; Martis, E.; Prieto, D.; Sabnis, S.C.; Amer, S.E.D.R.; Liew, A.W.C.; Perco, P.; Rahimi, F.; Riva, G.; Zhang, C.; Devkota, H.P.; Ogami, K.; Basharat, Z.; Fierz, W.; Siebers, R.; Tan, K.H.; Boehme, K.A.; Brenneisen, P.; Brown, J.A.L.; Dalrymple, B.P.; Harvey, D.J.; Ng, G.; Werten, S.; Bleackley, M.; Dai, Z.; Dhariwal, R.; Gelfer, Y.; Hartmann, M.D.; Miotla, P.; Tamaian, R.; Govender, P.; Gurney-Champion, O.J.; Kauppila, J.H.; Zhang, X.; Echeverría, N.; Subhash, S.; Sallmon, H.; Tofani, M.; Bae, T.; Bosch, O.; Cuív, P.O.; Danchin, A.; Diouf, B.; Eerola, T.; Evangelou, E.; Filipp, F.; Klump, H.; Kurgan, L.; Smith, S.S.; Terrier, O.; Tuttle, N. (2019) 'Large expert-curated database for benchmarking document similarity detection in biomedical literature search'. DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION, 2019 . [Link] [DOI] | |
| 2019 | Gullo, G.; J. Eustace, A.; Canonici, A.; M. Collins, D.; Kennedy, M.J.; Grogan, L.; Breathhnach, O.; McCaffrey, J.; Keane, M.; Martin, M.J.; Gupta, R.; Leonard, G.; O’Connor, M.; Calvert, P.M.; Donnellan, P.; Walshe, J.; McDermott, E.; Scott, K.; Hernando, A.; Parker, I.; W. Murray, D.; C. O’Farrell, A.; Maratha, A.; Dicker, P.; Rafferty, M.; Murphy, V.; O’Donovan, N.; M. Gallagher, W.; Ky, B.; Tryfonopoulos, D.; Moulton, B.; T. Byrne, A.; Crown, J. (2019) 'Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial'. Therapeutic Advances in Medical Oncology, 11 . [Link] [DOI] | |
| 2019 | Gaule, P.; Mukherjee, N.; Corkery, B.; Eustace, A.J.; Gately, K.; Roche, S.; O’Connor, R.; O’Byrne, K.J.; Walsh, N.; Duffy, M.J.; Crown, J.; O’Donovan, N. (2019) 'Dasatinib treatment increases sensitivity to c-met inhibition in triple-negative breast cancer cells'. Cancers, 11 . [Link] [DOI] | |
| 2018 | Eustace, A.J.; Conlon, N.T.; McDermott, M.S.J.; Browne, B.C.; O'Leary, P.; Holmes, F.A.; Espina, V.; Liotta, L.A.; O'Shaughnessy, J.; Gallagher, C.; O'Driscoll, L.; Rani, S.; Madden, S.F.; O'Brien, N.A.; Ginther, C.; Slamon, D.; Walsh, N.; Gallagher, W.M.; Zagozdzon, R.; Watson, W.R.; O'Donovan, N.; Crown, J. (2018) 'Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL'. BMC Cancer, 18 . [Link] [DOI] | |
| 2018 | Coté, D.; Eustace, A.; Toomey, S.; Cremona, M.; Milewska, M.; Furney, S.; Carr, A.; Fay, J.; Kay, E.; Kennedy, S.; Crown, J.; Hennessy, B.; Madden, S. (2018) 'Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)'. PLoS ONE, 13 . [Link] [DOI] | |
| 2018 | Elster N; Toomey S; Fan Y; Cremona M; Morgan C; Weiner Gorzel K; Bhreathnach U; Milewska M; Murphy M; Madden S; Naidoo J; Fay J; Kay E; Carr A; Kennedy S; Furney S; Mezynski J; Breathhnach O; Morris P; Grogan L; Hill A; Kennedy S; Crown J; Gallagher W; Hennessy B; Eustace A; (2018) 'Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer'. Therapeutic Advances in Medical Oncology, 10 . [DOI] | |
| 2018 | Milewska M; Cremona M; Morgan C; O'Shea J; Carr A; Velanki SH; Hopkins AM; Toomey S; Madden SF; Hennessy BT; Eustace AJ; (2018) 'Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers'. Therapeutic Advances in Medical Oncology, 10 . [DOI] | |
| 2017 | O'Shea J; Cremona M; Morgan C; Milewska M; Holmes F; Espina V; Liotta L; O'Shaughnessy J; Toomey S; Madden SF; Carr A; Elster N; Hennessy BT; Eustace AJ; (2017) 'A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib'. Oncotarget, 8 (49). [DOI] | |
| 2017 | Canonici, A; Qadir, Z; Conlon, NT; Collins, DM; O'Brien, NA; Walsh, N; Eustace, AJ; O'Donovan, N; Crown, J (2017) 'The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells'. Investigational New Drugs, 36 (4). [DOI] | |
| 2017 | Toomey, S.; Eustace, A.J.; Fay, J.; Sheehan, K.M.; Carr, A.; Milewska, M.; Madden, S.F.; Teiserskiene, A.; Kay, E.W.; O'Donovan, N.; Gallagher, W.; Grogan, L.; Breathnach, O.; Walshe, J.; Kelly, C.; Moulton, B.; Kennedy, M.J.; Gullo, G.; Hill, A.D.; Power, C.; Duke, D.; Hambly, N.; Crown, J.; Hennessy, B.T. (2017) 'Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies'. Breast Cancer Research, 19 . [Link] [DOI] | |
| 2016 | Toomey S; Madden SF; Furney SJ; Fan Y; McCormack M; Stapleton C; Cremona M; Cavalleri GL; Milewska M; Elster N; Carr A; Fay J; Kay EW; Kennedy S; Crown J; Gallagher WM; Hennessy BT; Eustace AJ; (2016) 'The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer'. Oncotarget, 7 (46). [DOI] | |
| 2015 | Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ; (2015) 'A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib'. Breast Cancer Research and Treatment, 149 (2). [DOI] | |
| 2015 | Mahgoub, T.; Eustace, A.J.; Collins, D.M.; Walsh, N.; O'Donovan, N.; Crown, J. (2015) 'Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma'. International Journal of Oncology, 47 . [Link] [DOI] | |
| 2015 | Collins DC; Cocchiglia S; Tibbitts P; Solon G; Bane FT; McBryan J; Treumann A; Eustace A; Hennessy B; Hill AD; Young LS; (2015) 'Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer'. Oncogene, 34 (4). [DOI] | |
| 2014 | Eustace, AJ; Kennedy, S; Larkin, AM; Mahgoub, T; Tryfonopoulos, D; O'Driscoll, L; Clynes, M; Crown, J; O'Donovan, N (2014) 'Predictive biomarkers for dasatinib treatment in melanoma'. ONCOSCIENCE, 1 (2). [DOI] | |
| 2014 | McDermott, M.; Eustace, A.J.; Busschots, S.; Breen, L.; Crown, J.; Clynes, M.; O'Donovan, N.; Stordal, B. (2014) 'In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: A practical guide with case studies'. Frontiers in Oncology, 4 MAR . [Link] [DOI] | |
| 2012 | Browne, B.C.; Eustace, A.J.; Kennedy, S.; O'Brien, N.A.; Pedersen, K.; McDermott, M.S.J.; Larkin, A.; Ballot, J.; Mahgoub, T.; Sclafani, F.; Madden, S.; Kennedy, J.; Duffy, M.J.; Crown, J.; O'Donovan, N. (2012) 'Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours'. Breast Cancer Research and Treatment, 136 . [Link] [DOI] | |
| 2011 | Brougham, D.F.; Ivanova, G.; Gottschalk, M.; Collins, D.M.; Eustace, A.J.; O'Connor, R.; Havel, J. (2011) 'Artificial neural networks for classification in metabolomic studies of whole cells using 1H Nuclear Magnetic Resonance'. Journal of Biomedicine and Biotechnology, 2011 . [Link] [DOI] | |
| 2010 | Walsh, N.; Kennedy, S.; Larkin, A.M.; Tryfonopoulos, D.; Eustace, A.J.; Mahgoub, T.; Conway, C.; Oglesby, I.; Collins, D.; Ballot, J.; Ooi, W.S.; Gullo, G.; Clynes, M.; Crown, J.; O'Driscoll, L. (2010) 'Membrane transport proteins in human melanoma: Associations with tumour aggressiveness and metastasis'. British Journal of Cancer, 102 . [Link] [DOI] | |
| 2010 | Eustace, AJ; Dowling, P; Henry, M; Doolan, P; Meleady, P; Clynes, M; Crown, J; O'Donovan, N (2010) '2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines'. Journal of Proteomics, 74 (4). [DOI] | |
| 2008 | Gottschalk, M.; Ivanova, G.; Collins, D.M.; Eustace, A.; O'Connor, R.; Brougham, D.F. (2008) 'Metabolomic studies of human lung carcinoma cell lines using in vitro 1H NMR of whole cells and cellular extracts'. NMR in Biomedicine, 21 . [Link] [DOI] | |
| 2008 | Ivanova, G. I.; Cabrita, E. J.; O'Connor, R.; Eustace, A. J.; Brougham, D. F. (2008) 'Application of diffusion-ordered spectroscopy for the analysis of cancer related biological samples'. Bulgarian Chemical Communications, 40 (4). | |
| 2008 | Glynn, S.A.; O'Sullivan, D.; Eustace, A.J.; Clynes, M.; O'Donovan, N. (2008) 'The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells'. BMC Cancer, 8 . [Link] [DOI] | |
| 2008 | Eustace, A.J.; Crown, J.; Clynes, M.; O'Donovan, N. (2008) 'Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines'. Journal of Translational Medicine, 6 . [Link] [DOI] | |
| 2023 | Gaynor, N.; Blanco, A.; Madden, S.F.; Moran, B.; Fletcher, J.M.; Kaukonen, D.; Ramírez, J.S.; Eustace, A.J.; McDermott, M.S.J.; Canonici, A.; Toomey, S.; Teiserskiene, A.; Hennessy, B.T.; O’Donovan, N.; Crown, J.; Collins, D.M. (2023) 'Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy'. British Journal of Cancer, 129 . [Link] [DOI] | |
| 2023 | Roche, S.; Gaule, P.; Winrow, D.; Mukherjee, N.; O’Neill, F.; Conlon, N.T.; Meiller, J.; Collins, D.M.; Canonici, A.; Fawsi, M.I.; Estepa-Fernández, A.; Madden, S.F.; Crown, J.; O’Donovan, N.; Eustace, A.J. (2023) 'Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer'. PLoS ONE, 18 . [Link] [DOI] |
Conference Contribution
Other Publication
| Year | Publication | |
|---|---|---|
| 2022 | Eustace, A.J.; Lee, M.J.; Colley, G.; Roban, J.; Downing, T.; Buchanan, P.J. (2022) Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer. [Link] [DOI] | |
| 2015 | Elster, N.; Collins, D.M.; Toomey, S.; Crown, J.; Eustace, A.J.; Hennessy, B.T. (2015) HER2-family signalling mechanisms, clinical implications and targeting in breast cancer. [Link] [DOI] | |
| 2022 | Kennedy, SP; Treacy, O; Allott, EH; Eustace, AJ; Lynam-Lennon, N; Buckley, N; Robson, T (2022) Precision Medicine and Novel Therapeutic Strategies in Detection and Treatment of Cancer: Highlights from the 58th IACR Annual Conference. [DOI] | |
| 2016 | Toomey, S.; Eustace, A.J.; Pritzker, L.B.; Pritzker, K.P.H.; Fay, J.; O'Grady, A.; Cummins, R.; Grogan, L.; Kennedy, J.; O'Connor, D.; Young, L.; Kay, E.W.; O'Donovan, N.; Gallagher, W.M.; Kalachand, R.; Crown, J.; Hennessy, B.T. (2016) RE: RNA disruption assay as a biomarker of pathological complete response in Neoadjuvant Trastuzumab-treated human epidermal growth factor receptor 2-positive breast cancer. [Link] [DOI] | |
| 2014 | Browne, B.C.; Eustace, A.J.; Kennedy, S.; O’Brien, N.A.; Pedersen, K.; McDermott, M.S.J.; Larkin, A.; Ballot, J.; Mahgoub, T.; Sclafani, F.; Madden, S.; Kennedy, J.; Duffy, M.J.; Crown, J.; O’Donovan, N. (2014) Erratum to: Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours (Breast Cancer Res Treat, (2012), 136, (717-727), 10.1007/s10549-012-2260-9). [Link] [DOI] | |
| 2024 | Bartkowski, M.; Zhou, Y.; Nabil Amin Mustafa, M.; Eustace, A.J.; Giordani, S. (2024) CARBON DOTS: Bioimaging and Anticancer Drug Delivery. [Link] [DOI] |
Conference Publication
Certain data included herein are derived from the © Web of Science (2025) of Clarivate. All rights reserved.
Employment
Education
Research Interests
- Translational Oncology
- Genomic analysis of cancer to identify novel biomarkers of response and resistance to therapeutics
- Drug repurposing to identify novel treatments for hard to treat cancers